V920 is a recombinant, replication-competent vaccine, consisting of a vesicular stomatitis virus (VSV), which has been genetically engineered to express a glycoprotein from the Zaire ebolavirus so as to provoke a neutralizing immune response to the Ebola virus.
Merck's V920 (rVSVΔG-ZEBOV-GP) investigational vaccine candidate prevents the onset of Ebola Zaire.
And since the beginning of the DRC vaccination program on August 8, 2018, approximately 111,920 persons have been vaccinated with Merck’s v920.
Moreover, a recent analysis estimated v920’s Vaccine Efficacy at 97.5 percent.
The Democratic Republic of Congo's Health Minister called for Merck’s experimental Ebola vaccine v920 (rVSV∆G-ZEBOV-GP) to be fully licensed.
Dr. Kalenga said he ‘preferred to use just one Ebola vaccine, stating, “It would perturb the population to be faced with several different types of vaccines and that would muddle the message. And, as you know in complex outbreak response, the message needs to be simple and clear.”
The process of creating vaccination rings around all people at risk of contracting Ebola has been an effective way to prevent more people from becoming infected.
Additionally, the use of pop-up and targeted geographic approaches to identify those needing vaccination make the ring vaccination process faster, more secure, and more responsive to community feedback.
Furthermore, vaccinating those who could be part of tertiary chains of transmission, such as people in villages and neighborhoods where cases have been reported within the past 21 days has helped prevent the spread.
Clinical Trial: NCT02503202 Phase 3: Evaluation of the Safety and Immunogenicity of Three Consistency Lots and a High-Dose Lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in Healthy Adults (V920-012)
- This Phase 3 study evaluated the safety and immunogenicity of 3 consistency lots and a high-dose lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in healthy adults. The primary purpose of this study was to demonstrate consistency in the immune responses of participants receiving 3 separate lots of V920 through 28 days postvaccination. In addition to the 3 lot groups, a high-dose group and a placebo group were studied. A subset of participants representative of all treatment groups continued through 24 months postvaccination in the extension study for the evaluation of long-term safety. The primary hypothesis states that the geometric mean titer of anti-Zaire ebolavirus envelope (ZEBOV) glycoprotein antibody at 28 days postvaccination is equivalent across the three consistency lots.
Clinical Trial: NCT03031912 Phase 2: African-Canadian Study of HIV-Infected Adults and a Vaccine for Ebola - ACHIV-Ebola
- This Phase 2 study s a randomized, placebo-controlled, multi-site, double-blind trial of V920 (rVSVΔG-ZEBOV-GP) Ebola Virus vaccine candidate in subjects with HIV infection to be conducted in conformance with Good Clinical Practices. The study will take place at 2 Canadian sites (Centre Hospitalier de l'Université de Montréal and Ottawa General Hospital) and 2 African sites (Centre MURAZ, Burkina Faso and Centre Hospitalier National Aristide Le Dantec, Dakar, Senegal).